BMS, VantAI team up; CRISPR Therapeutics to raise $280M; Ono Pharma’s deal with Shattuck Labs

Plus, news about Areteia Ther­a­peu­tics, Su­do Bio­sciences, Cidara Ther­a­peu­tics, Xspray Phar­ma and Sana Biotech­nol­o­gy:

Bris­tol My­ers Squibb inks deal with Van­tAI: The pair plan to use Van­tAI’s gen­er­a­tive AI plat­form to de­sign mol­e­c­u­lar glues as small mol­e­cule drugs, with the op­tion to ex­pand to more pro­grams in the fu­ture. Van­tAI could re­ceive up to $674 mil­lion in mile­stones plus tiered roy­al­ties. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.